Table 3.
Details of the unmatched in situ hybridisation cases
| Case ID | PathVysion | PharmDx™ | INFORM | CISH | ||||
| HER2 signals per nucleus | CEP17 signals per nucleus | Ratio | HER2 signals per nucleus | CEP17 signals per nucleus | Ratio | HER2 signals per nucleus | HER2 signals per nucleus | |
| 20 | 5.6 | 5.3 (P) | 1.1 | 6.2 | 4.0 (P) | 1.6 | 4.9 | 6.4 |
| 21 | 2.2 | 2.5 | 0.9 | 5.1 | 3.3 (P) | 1.6 | 5.6 | 5.6 |
| 22 | - | - | - | 4.5 | 2.0 | 2.3 | 3.8 | 3.6 |
| 24 | 2.6 | 2.5 | 1.0 | 3.3 | 2.6 | 1.2 | 4.3 | Clusters |
| 25 | 3.7 | 3.8 (P) | 1.0 | 6.2 | 4.0 (P) | 1.6 | 7.7 | 5.5 |
| 26 | 4.4 | 2.8 | 1.6 | 6.1 | 4.2 (P) | 1.5 | 5.3 | 6.6 |
| 27 | 3.4 | 2.2 | 1.5 | 3.8 | 2.4 | 1.6 | 4.8 | 3.7 |
| 28 | 3.8 | 3.7 (P) | 1.0 | 4.0 | 3.4 (P) | 1.2 | 5.7 | 4.9 |
| 29 | 2.0 | 2.0 | 1.0 | 3.5 | 2.0 | 1.7 | 4.4 | 3.6 |
| 30 | 4.6 | 3.3 (P) | 1.4 | 5.7 | 3.7 (P) | 1.5 | 5.5 | 3.4 |
| 32 | 2.0 | 2.5 | 0.8 | 2.0 | 2.0 | 1.0 | 4.2 | 4.9 |
| 33 | 5.6 | 5.0 (P) | 1.1 | 5.2 | 3.5 (P) | 1.5 | 4.5 | 5.7 |
| 34 | 3.3 | 2.2 | 1.5 | 3.3 | 2.1 | 1.6 | 4.1 | 2.5 |
| 35 | 3.1 | 3.5 (P) | 0.9 | 2.8 | 2.7 | 1.0 | 4.2 | 3.3 |
HER2, human epidermal growth factor receptor 2; CEP17, chromosome enumeration probe 17; P, polysomy; CISH, chromogenic in situ hybridisation.